NCT05437120View on ClinicalTrials.gov

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 22, 2022

Primary Completion Date

March 16, 2023

Study Completion Date

March 16, 2023

Conditions
Cystic Fibrosis
Interventions
DRUG

VX-121/TEZ/D-IVA

Fixed-dose combination tablets for oral administration.

Trial Locations (2)

33705

GCP Research, St. Petersburg

33014-3616

Clinical Pharmacology of Miami, LLC, Miami

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY